Targeting neurotrophic factor pathways (e.g., NGF/TrkA inhibitors, anti-BDNF monoclonal antibodies), as well as modulating axon guidance signaling (e.g., semaphorin receptor antagonists), has demonstrated potential in preclinical models to attenuate perineural tumor growth, mitigate associated neuropathic pain, and improve responsiveness to conventional therapies [61,62,63,64]. This evidence concerns the gene NTF3 and neoplasm.